(1) Background: Numerous vaccines are under preclinical and clinical development for
prevention of severe course and lethal outcome of coronavirus disease 2019 (COVID-19). In …

Objectives To describe the safety of vaccines against SARS-CoV-2 in people with
inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods …

Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Background We describe the early experiences of adults with systemic rheumatic disease
who received the COVID-19 vaccine. Methods From 2 April to 30 April 2021, we conducted …

Abstract Coronavirus disease 2019 (COVID-19) is a real challenge for humanity with high
morbidity and mortality. Despite being primarily a respiratory illness, COVID-19 can affect …

В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2),
вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19) …

Objective To describe the rate and type of adverse effects (AEs) and the frequency of
disease flares after COVID-19 vaccination and to assess the reasons for vaccination …

Purpose Vaccine-associated hypermetabolic lymphadenopathy (VAHL) is frequently
observed on [18F] FDG PET-CT following BNT162b2 administration. Recent data suggest a …

Immunocompromised patients are considered high-risk and prioritized for vaccination
against COVID-19. We aimed to analyze B-cell subsets in these patients to identify potential …